Healthcare use by varied highly active antiretroviral therapy (HAART) strata: HAART use, discontinuation, and naivety

AIDS

Volumn 18, Issue 4, 2004, Pages 621-630

  Palacio, Herminia ^a   Li, Xiuhong ^b   Wilson, Tracey E ^c   Sacks, Henry ^d   Cohen, Mardge H ^e   Richardson, Jean ^f   Young, Mary ^g   Muñoz, Alvaro ^b  

^a Harris Co Pub Hlth Environ Serv   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Jr Hospital of Cook County   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; HAART; Healthcare; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; EMERGENCY WARD; EMPLOYMENT; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DELIVERY OF HEALTH CARE; EMERGENCY SERVICE, HOSPITAL; FEMALE; HIV INFECTIONS; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; ODDS RATIO; PATIENT ACCEPTANCE OF HEALTH CARE; PRIMARY HEALTH CARE; UNITED STATES; WOMEN'S HEALTH SERVICES;

EID: 1642372723     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200403050-00006     Document Type: Article

References (40)

1. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74-80.
2. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182-189.
3. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
4. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-F70.
5. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23:35-43.
6. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000, 160:2050-2056.
7. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000, 31: 162-166.
8. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14:F25-32.
9. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001, 15:717-723.
10. Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr 2000, 25(Suppl 1):S4-S11.
11. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997, 336: 1531-1532.
12. Keiser P, Kvanli MB, Turner D, Reisch J, Smith JW, Nassar N, et al. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. J Acquir Immune Def Syndr Hum Retrovirol 1999, 20:28-33.
13. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999, 13: 415-418.
14. Fleishman JA, Hellinger FJ. Trends in HIV-related inpatient admissions from 1993 to 1997: a seven-state study. J Acquir Immune Defic Syndr 2001, 28:73-80.
15. Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J Acquir Immune Defic Syndr 2001, 27:14-19.
16. Paul S, Gilbert HM, Lande L, et al. Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001. AIDS Res Hum Retroviruses 2002, 18: 501-506.
17. Mole L, Ockrim K, Holodniy M. Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. Pharmacoeconomics 1999, 16:307-315.
18. Lapins DL, Urdaneta ME, Barrett J, Hamel EC, Duong PT, Markson LE. Costs of care for HIV infection in a managed care population from 1995 to 1997. Am J Manag Care 2000, 6: 973-981.
19. Bidwell Goetz M, Morreale AP, Rhew DC, Berman S, Ing M, Eldridge D, et al. Effect of highly active antiretroviral therapy on outcomes in Veterans Affairs Medical Centers. AIDS 2001, 15:530-532.
20. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001, 344:817-823.
21. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999, 13:963-969.
22. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:143-152.
23. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr 2002, 30:21-26.
24. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998, 9:117-125.
25. Munoz A, Gange SJ, Jacobson LP. Distinguishing efficacy, individual effectiveness, and population effectiveness of therapies. AIDS 2000, 14:754-756.
26. Ahdieh L, Gange SJ, Greenblatt R, Minkoff H, Anastos K, Young M, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol 2000, 152:923-933.
27. Cook JA, Cohen MH, Grey D, Kirstein L, Burke J, Anastos K, et al. Use of highly active antiretroviral therapy in a cohort of HIV-seropositive women. Am J Public Health 2002, 92:82-87.
28. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:1-19.
29. Hessol NA, Schwarcz S, Ameli N, Oliver G, Greenblatt RM. Accuracy of self-reports of acquired immunodeficiency syndrome and acquired immunodeficiency syndrome-related conditions in women. Am J Epidemiol 2001, 153:1128-1133.
30. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. 1998 (June):1-54.
31. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation; 1998 (December):1-50.
32. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation; 1999 (May):1-52.
33. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. January ed: Department of Health and Human Services and Henry J. Kaiser Family Foundation; 2000:1-101.
34. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
35. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
36. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381-390.
37. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report: U.S. HIV and AIDS Cases Reported Through December 2000. Atlanta: CDC; 2000:1-48.
38. Kahn JG. Expenditures for the care of patients with HIV [correspondence]. N Engl J Med 2001, 344:1948-1949.
39. Bozzette SA, Joyce G, McCaffrey DF. Expenditures for the care of patients with HV [correspondence]. N Engl J Med 2001, 344:1948-1949.
40. Frankel MR, Shapiro MF, Duan N, Morton SC, Berry SH, Brown JA, et al. National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample. Health Serv Res 1999, 34:969-992.